protein aggregation

Israeli biotechnology company BioBlast is developing and testing Cabaletta, designed to counteract abnormal clumping of cellular proteins in oculopharnyngeal muscular dystrophy (OPMD)

posted on November 18, 2014 - 10:00am
Update (March 17, 2015): In a March 12, 2015, press release, BioBlast announced it will open a site for the Cabaletta in OPMD study in California during the second quarter of 2015.

New content is being added every day. Please check back again.